Displaying 1201 - 1220 of 4794
1911005 Informal Interpretation
2002002 Informal Interpretation
FTC and DOJ Extend Deadline for Public Comments on Draft Vertical Merger Guidelines, Announce Two Related Public Workshops
Vertical Merger Guidelines Workshop - CANCELED
FTC, FDA Sign Joint Statement Promoting Competition in Markets for Biologics
Joint FDA-FTC Statement Regarding Collaboration to Advance Competition in the Biologic Marketplace
FTC Files Suit to Block Edgewell Personal Care Company’s Acquisition of Harry’s, Inc.
Should We Block This Merger? Some Thoughts on Converging Antitrust and Privacy
Statement of the FTC Chairman Regarding Announcement that Aveanna Healthcare and Maxim Healthcare Services have Terminated Their Acquisition Agreement
FTC Announces Annual Update of Size of Transaction Thresholds for Premerger Notification Filings and Interlocking Directorates
FTC Extends Deadline for Comments on Workshop Addressing Non-Compete Clauses in Employment Contracts
FTC and NY Attorney General Charge Vyera Pharmaceuticals, Martin Shkreli, and Other Defendants with Anticompetitive Scheme to Protect a List-Price Increase of More Than 4,000 Percent for Life-Saving Drug Daraprim
Illumina Inc./Pacific Biosciences of California, Inc., In the Matter of
The Federal Trade Commission authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California, alleging in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing systems by extinguishing PacBio as a nascent competitive threat. The Commission vote to issue the administrative complaint and to authorize staff to seek a temporary restraining order and preliminary injunction was 5-0. On Jan. 2, 2020, the parties abandoned the transaction.
FTC Seeks Public Comment on Par Petroleum Corp.’s Application to Modify Agreement to Store Petroleum Products at Barbers Point Terminal in Hawaii
Displaying 1201 - 1220 of 4794